Literature DB >> 2894810

HTLV-I-associated leukemia: a model for chronic retroviral diseases.

E L Murphy1, W A Blattner.   

Abstract

Human T-lymphotropic virus type I (HTLV-I) has been associated with adult T-cell leukemia/lymphoma (ATL), a malignancy of mature CD4-positive lymphocytes, and with tropical spastic paraparesis (TSP), a demyelinating neurological syndrome. This article describes the clinical and pathological features of ATL and reviews the epidemiology of this disease and of its putative etiological agent, HTLV-I. From what is known about the molecular biology and epidemiology of HTLV-I, hypotheses on the etiology of TSP are proposed, and strategies for studying the neurological syndrome are suggested.

Entities:  

Mesh:

Year:  1988        PMID: 2894810     DOI: 10.1002/ana.410230739

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  5 in total

1.  Spontaneous cell proliferation is associated with poor sensitivity to glucocorticoids in patients infected with HTLV.

Authors:  R P Lopes; M Menna-Barreto; M E Bauer
Journal:  Cell Prolif       Date:  2007-02       Impact factor: 6.831

2.  Human T-lymphotropic virus type II seroprevalence among emergency department and clinic patients.

Authors:  D Agranoff; K Varney; H Khayam-Bashi; E L Murphy
Journal:  West J Med       Date:  1996-06

Review 3.  Viruses in the mammalian male genital tract and their effects on the reproductive system.

Authors:  N Dejucq; B Jégou
Journal:  Microbiol Mol Biol Rev       Date:  2001-06       Impact factor: 11.056

4.  Human T-lymphotropic virus type I seroprevalence among Japanese Americans.

Authors:  E L Murphy; K F Varney; N T Miyasaki; R J Moore; J I Umekubo; A N Watanabe; H Khayam-Bashi
Journal:  West J Med       Date:  1993-05

5.  Human T-Lymphotropic Virus (HTLV) Type I in vivo Integration in Oral Keratinocytes.

Authors:  Martha C Domínguez; Norma Enith González; Adalberto Sánchez; Felipe García Vallejo
Journal:  Braz J Microbiol       Date:  2011-01       Impact factor: 2.476

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.